Market Closed -
Canadian Securities Exchange
20:47:28 26/04/2024 BST
|
5-day change
|
1st Jan Change
|
0.28
CAD
|
+1.82%
|
|
+3.70%
|
-9.68%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
17.71
|
49.06
|
157.2
|
39.6
|
62.67
|
Enterprise Value (EV)
1 |
15.81
|
46.76
|
146.2
|
34.68
|
58.82
|
P/E ratio
|
-4.45
x
|
-4.28
x
|
-14.1
x
|
-10.5
x
|
-12.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
6,132,126,693
x
|
802,166,588
x
|
15,473,823
x
|
4,588,686
x
|
EV / Revenue
|
-
|
6,132,126,405
x
|
802,166,532
x
|
15,473,821
x
|
4,588,686
x
|
EV / EBITDA
|
-5,906,670
x
|
-10,471,080
x
|
-21,140,869
x
|
-6,354,920
x
|
-16,622,728
x
|
EV / FCF
|
-18,300,682
x
|
16,380,320
x
|
-21,223,270
x
|
-6,340,166
x
|
-87,053,562
x
|
FCF Yield
|
-0%
|
0%
|
-0%
|
-0%
|
-0%
|
Price to Book
|
12.5
x
|
-13.7
x
|
17.4
x
|
6.19
x
|
15.3
x
|
Nbr of stocks (in thousands)
|
143,866
|
186,523
|
248,490
|
249,728
|
268,002
|
Reference price
2 |
0.1231
|
0.2630
|
0.6327
|
0.1586
|
0.2338
|
Announcement Date
|
08/04/20
|
31/03/21
|
31/03/22
|
30/03/23
|
01/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
0.008
|
0.196
|
2.559
|
13.66
|
EBITDA
|
-
|
-2.998
|
-4.685
|
-7.437
|
-6.231
|
-3.77
|
EBIT
1 |
-0.3343
|
-3.001
|
-4.725
|
-7.48
|
-6.266
|
-3.803
|
Operating Margin
|
-
|
-
|
-59,062.5%
|
-3,816.33%
|
-244.86%
|
-27.85%
|
Earnings before Tax (EBT)
1 |
-0.3343
|
-3.335
|
-9.953
|
-10.09
|
-3.888
|
-4.034
|
Net income
1 |
-0.3343
|
-3.335
|
-9.953
|
-10.05
|
-3.764
|
-4.7
|
Net margin
|
-
|
-
|
-124,412.5%
|
-5,126.02%
|
-147.09%
|
-34.41%
|
EPS
2 |
-0.1742
|
-0.0276
|
-0.0614
|
-0.0447
|
-0.0151
|
-0.0183
|
Free Cash Flow
|
-
|
-0.9676
|
2.995
|
-7.408
|
-6.246
|
-0.7199
|
FCF margin
|
-
|
-
|
37,435.94%
|
-3,779.66%
|
-244.06%
|
-5.27%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
31/05/19
|
08/04/20
|
31/03/21
|
31/03/22
|
30/03/23
|
01/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
1.9
|
2.3
|
11
|
4.91
|
3.85
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-0.97
|
2.99
|
-7.41
|
-6.25
|
-0.72
|
ROE (net income / shareholders' equity)
|
-
|
-433%
|
907%
|
-373%
|
-51.1%
|
-80.1%
|
ROA (Net income/ Total Assets)
|
-
|
-116%
|
-85.4%
|
-55.3%
|
-40.1%
|
-34.2%
|
Assets
1 |
-
|
2.882
|
11.65
|
18.17
|
9.395
|
13.76
|
Book Value Per Share
2 |
0.0100
|
0.0100
|
-0.0200
|
0.0400
|
0.0300
|
0.0200
|
Cash Flow per Share
|
-
|
0.0100
|
0.0100
|
0.0400
|
0.0200
|
0.0100
|
Capex
|
-
|
0.01
|
-
|
0.04
|
0.03
|
0.05
|
Capex / Sales
|
-
|
-
|
-
|
20.92%
|
1.02%
|
0.34%
|
Announcement Date
|
31/05/19
|
08/04/20
|
31/03/21
|
31/03/22
|
30/03/23
|
01/04/24
|
|
1st Jan change
|
Capi.
|
---|
| -9.68% | 57.41M | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|